JP7796718B2 - 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法 - Google Patents

閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法

Info

Publication number
JP7796718B2
JP7796718B2 JP2023501090A JP2023501090A JP7796718B2 JP 7796718 B2 JP7796718 B2 JP 7796718B2 JP 2023501090 A JP2023501090 A JP 2023501090A JP 2023501090 A JP2023501090 A JP 2023501090A JP 7796718 B2 JP7796718 B2 JP 7796718B2
Authority
JP
Japan
Prior art keywords
minutes
pharmaceutically acceptable
acceptable salt
thc
osa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533289A (ja
JP2023533289A5 (enExample
Inventor
ブリークレイ，マーク・ロバート
アガーワル，スダンシュ
レイサム，ジョエル・ブラッドリー
Original Assignee
インカネックス・ヘルスケア・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902368A external-priority patent/AU2020902368A0/en
Application filed by インカネックス・ヘルスケア・リミテッド filed Critical インカネックス・ヘルスケア・リミテッド
Publication of JP2023533289A publication Critical patent/JP2023533289A/ja
Publication of JP2023533289A5 publication Critical patent/JP2023533289A5/ja
Application granted granted Critical
Publication of JP7796718B2 publication Critical patent/JP7796718B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023501090A 2020-07-09 2021-07-09 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法 Active JP7796718B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902368 2020-07-09
AU2020902368A AU2020902368A0 (en) 2020-07-09 A method of treatment
PCT/AU2021/050734 WO2022006636A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (osa)

Publications (3)

Publication Number Publication Date
JP2023533289A JP2023533289A (ja) 2023-08-02
JP2023533289A5 JP2023533289A5 (enExample) 2024-07-09
JP7796718B2 true JP7796718B2 (ja) 2026-01-09

Family

ID=79553355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501090A Active JP7796718B2 (ja) 2020-07-09 2021-07-09 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法

Country Status (8)

Country Link
US (1) US20230310364A1 (enExample)
EP (1) EP4178568A4 (enExample)
JP (1) JP7796718B2 (enExample)
AU (1) AU2021306424A1 (enExample)
CA (1) CA3182528A1 (enExample)
CO (1) CO2023000118A2 (enExample)
IL (1) IL299212A (enExample)
WO (1) WO2022006636A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023289652A1 (en) * 2022-06-21 2024-12-12 Apnimed, Inc. (Delaware) Methods of treating sleep apnea with a combination of a cannabinoid and a carbonic anhydrase inhibitor
AU2023404665A1 (en) * 2022-11-29 2025-07-17 Incannex Healthcare Limited A method of treating obstructive sleep apnoea (osa)
WO2025107039A1 (en) * 2023-11-23 2025-05-30 Incannex Healthcare Limited Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071302A1 (en) 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5714910B2 (ja) * 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
EP3746068A4 (en) * 2018-01-29 2021-11-03 Evero COMPOSITIONS AND METHODS OF TREATMENT FOR OBSTRUCTIVE SLEEP APNEA
WO2019180706A1 (en) * 2018-03-19 2019-09-26 Bol Pharma Ltd. Methods and compositions for treating epilepsy and associated disorders
CN117177741A (zh) * 2021-04-16 2023-12-05 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019071302A1 (en) 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bradley A. Edwards et al.，Sleep，2013年，Vol.36, No.2，DOI:10.5665/sleep.2390
David W. Carley et al.，Sleep，2018年，Vol.41, No.1，DOI:10.1093/sleep/zsx184

Also Published As

Publication number Publication date
AU2021306424A1 (en) 2023-01-19
CA3182528A1 (en) 2022-01-13
JP2023533289A (ja) 2023-08-02
US20230310364A1 (en) 2023-10-05
IL299212A (en) 2023-02-01
EP4178568A4 (en) 2024-10-16
WO2022006636A1 (en) 2022-01-13
EP4178568A1 (en) 2023-05-17
CO2023000118A2 (es) 2023-04-17

Similar Documents

Publication Publication Date Title
JP2023533289A (ja) 閉塞性睡眠時無呼吸（ｏｓａ）の治療のための組成物および方法
US6207190B1 (en) Dosage forms for the treatment of the chronic glaucomas
York Design of dosage forms
JPH09503778A (ja) 鎮痛剤およびその使用
JP3977724B2 (ja) 医薬組成物
MX2011007759A (es) Analogos de bumetanida, furosemida, piretanida, azosemida y torsemida, composiciones y metodos de uso.
WO2012166909A1 (en) Compositions and methods for treating breathing control disorders or diseases
CN109069495A (zh) 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
TW524690B (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
US6005009A (en) Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof
CN120549930A (zh) 用于增强生物利用度和电压门控钾离子通道开放暴露的方法
AU2024205127B2 (en) Compositions and methods for treating epilepsy
Virkkilä et al. Dexmedetomidine as intramuscular premedication in outpatient cataract surgery: a placebo‐controlled dose‐ranging study
CN110974828A (zh) 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物
JP2025530256A (ja) ストレス関連障害の治療のためのｍｄｍａの使用
EP1944030B1 (en) Agent for treatment of schizophrenia
CN1625402A (zh) 4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并(2,3－d)－嘧啶用于治疗尿失禁的用途
KR20250145687A (ko) 류마티스 관절염의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
KR20250141841A (ko) 다발성 경화증의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
JP2009196972A (ja) 医薬組成物
DE69919191T2 (de) Heilmittel für die stenose des rückenmarkkanals
JP7823051B2 (ja) 高血圧を処置する為の医薬組成物及び方法
KR20250145688A (ko) 당뇨병 및 당뇨 전단계의 치료에 있어서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복시산의 용도
CN108524481A (zh) 丙酸及其盐在制备防治精神类疾病、心脑血管疾病的药物及调理该疾病的保健品中的应用
KR20070085508A (ko) 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251223

R150 Certificate of patent or registration of utility model

Ref document number: 7796718

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150